secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001437749-24-009047
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports FY2023 net loss of $29.8M; cash runway into Q4 2024
---------------------------------------------------------------------

- Net loss $29.8M for fiscal year ended Dec 31, 2023; no revenue reported (pre-revenue biotech).
- R&D expenses $19.5M, up $0.5M YoY driven by $1.5M WPD sublicense termination; G&A $10.0M, down $1.5M.
- Cash and equivalents $23.6M at year-end; management expects runway into Q4 2024.
- Closed $4.5M registered direct offering and private placement with institutional investor and insiders.
- Positive interim Annamycin data in AML; plans to advance into pivotal Phase 2B/3 trial in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774924009047/0001437749-24-009047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774924009047/mbrx20240321_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-009047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer